A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma

Lim H.Y.Heo J.Choi H.J.Lin C.-Y.Yoon J.-H.CHIUN HSURau K.-M.Poon R.T.P.Yeo W.Park J.-W.Tay M.H.Hsieh W.-S.Kappeler C.Rajagopalan P.Krissel H.Jeffers M.Yen C.-J.Tak W.Y.2022-08-192022-08-1920141078-0432https://www.scopus.com/inward/record.uri?eid=2-s2.0-84918777261&doi=10.1158%2f1078-0432.CCR-13-3445&partnerID=40&md5=ce944a38d71e63767dc31015461398c3https://scholars.lib.ntu.edu.tw/handle/123456789/617146A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinomajournal article10.1158/1078-0432.CCR-13-3445252948972-s2.0-84918777261